PENTAXIM (one-dose booster)

Phase 1Biologic

IInstitute of Medical Biology, Chinese Academy of Medical Sciences

PENTAXIM (one-dose booster) is one of 20 biologic programs targeting Diphtheria. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

DiphtheriaActive, not recruiting

DiphtheriaPhase 1

Active, not recruiting

Competition

Competitive Landscape

70 competitors in Diphtheria

#DrugCompanyPhaseTrials

Comparator: Pbo

Merck & Co.

Approved

2 2

Boostrix

GSK

Approved

2 3

Rotateq

Merck & Co.

Approved

1 4

GSK 257049

GSK

Phase 3

2 5

Infanrix

GSK

Phase 3

1 6

Havrix

GSK

Phase 3

1 7

Rsvpref3 Vaccine

GSK

Phase 2

1 8

Acthib

GSK

Phase 3

1 9

REVAXIS

Sanofi

Phase 3

1 10

Vi-Polysaccharide Vaccine

Novartis

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 1Recruiting

Diphtheria

NCT06184542

Clinical

Trials by Indication[1]

Diphtheria1 trial

Phase I Clinical Trial of Diphtheria-Tetanus-acellular Pertussis Component Combined Vaccine

Recruiting·IInstitute of Medical Biology, Chinese Academy of Medical Sciences·Phase 1·NCT06184542·460 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for PENTAXIM (one-dose booster). U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — PENTAXIM (one-dose booster) compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for PENTAXIM (one-dose booster). EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Institute of Medical Biology, Chinese Academy of Medical Sciences company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 1[1]
Company: IInstitute of Medical Biology, Chinese Academy of Medical Sciences

PENTAXIM (one-dose booster)

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Trials by Indication[1]

Diphtheria1 trial

References

Drug Info

Quick Facts

Related News